45 results on '"Brown, Bob D."'
Search Results
2. First-in-human randomized study of RNAi therapeutic RG6346 for chronic hepatitis B virus infection
3. Hepatic Lactate Dehydrogenase A: An RNA Interference Target for the Treatment of All Known Types of Primary Hyperoxaluria
4. Data from Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin
5. Supplementary legends from β-Catenin mRNA Silencing and MEK Inhibition Display Synergistic Efficacy in Preclinical Tumor Models
6. Data from β-Catenin mRNA Silencing and MEK Inhibition Display Synergistic Efficacy in Preclinical Tumor Models
7. Figure S1, Figure S2, Figure S3 from β-Catenin mRNA Silencing and MEK Inhibition Display Synergistic Efficacy in Preclinical Tumor Models
8. supplemental figure legends from Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin
9. Supplemental figures S1-9 from Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin
10. Inhibition of Glycolate Oxidase With Dicer-substrate siRNA Reduces Calcium Oxalate Deposition in a Mouse Model of Primary Hyperoxaluria Type 1
11. Hepatic Lactate Dehydrogenase A : An RNA Interference Target for the Treatment of All Known Types of Primary Hyperoxaluria
12. Therapeutic RNA interference: A novel approach to the treatment of primary hyperoxaluria
13. Downregulation of BCL-2 Induces Downregulation of Carbonic Anhydrase IX, Vascular Endothelial Growth Factor, and pAkt and Induces Radiation Sensitization
14. Therapeutic RNA interference: A novel approach to the treatment of primary hyperoxaluria.
15. Glutathione and Bcl-2 targeting facilitates elimination by chemoradiotherapy of human A375 melanoma xenografts overexpressing bcl-xl, bcl-2, and mcl-1
16. Abstract 1502: KRAS RNAi therapy in preclinical models of pancreatic cancer sensitizes tumors to checkpoint blockade by affecting the tumor microenvironment
17. RNAi-Mediated β-Catenin Inhibition Promotes T Cell Infiltration and Antitumor Activity in Combination with Immune Checkpoint Blockade
18. Abstract B03: RNAi-mediated β-catenin inhibition sensitizes noninflamed tumors to immune checkpoint blockade
19. Direct Inhibition of β-catenin: A new strategy for colorectal cancer
20. Specific Inhibition of Hepatic Lactate Dehydrogenase Reduces Oxalate Production in Mouse Models of Primary Hyperoxaluria
21. Inhibition of Glycogen Synthase II with RNAi Prevents Liver Injury in Mouse Models of Glycogen Storage Diseases
22. Abstract 2759: Rational combinations for immune checkpoint blockade using β-catenin RNAi therapy
23. Effect of RNAi-based β-catenin inhibition on immunosuppressive Wnt-activated tumors in combination with IDOi/PD-1 immunotherapy.
24. β-Catenin mRNA Silencing and MEK Inhibition Display Synergistic Efficacy in Preclinical Tumor Models
25. Abstract 1229: RNAi-based β-catenin inhibition in combination with MEK inhibition promotes synergistic anti-tumor efficacy and overcomes resistance with MEK inhibition promotes synergistic anti-tumor efficacy and overcomes resistance
26. RNAi-mediated beta-catenin inhibition to promote T-cell infiltration and antitumor activity in combination with immune checkpoint blockade.
27. RNAi mediated silencing of STAT3/PD-L1in tumor-associated immune cells induces robust anti-tumor effects in immunotherapy resistant tumors
28. Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin
29. Chipping away at the ADA.
30. Abstract B20: EnCore-LNP mediated tumor delivery of MYC and CTNNB1 Dicer Substrate RNAs (DsiRNAs)
31. Knockdown of β-catenin with Dicer-Substrate siRNAs Reduces Liver Tumor Burden In vivo
32. Glutathione and Bcl-2 targeting facilitates elimination by chemoradiotherapy of human A375 melanoma xenografts overexpressing bcl-xl, bcl-2, and mcl-1
33. Quantitative Analysis of Dicer Substrate Oligonucleotides in Mouse Liver by Ultra-High-Performance Liquid Chromatography–Electrospray Ionization Tandem Mass Spectrometry
34. Irradiation of Human Prostate Cancer Cells Increases Uptake of Antisense Oligodeoxynucleotide
35. Bcl-2 and Glutathione Depletion Sensitizes B16 Melanoma to Combination Therapy and Eliminates Metastatic Disease
36. Comparison of D-G3139 and Its Enantiomer L-G3139 in Melanoma Cells Demonstrates Minimal In Vitro but Dramatic In Vivo Chiral Dependency
37. Knock-down of Bcl-2 by antisense oligodeoxynucleotides induces radiosensitization and inhibition of angiogenesis in human PC-3 prostate tumor xenografts
38. Bcl-2 Protein in 518A2 Melanoma Cells In vivo and In vitro
39. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice
40. Description of the Intrafollicular Delivery of Large Molecular Weight Molecules to Follicles of Human Scalp Skin In Vitro
41. Description of the intrafollicular delivery of large molecular weight molecules to follicles of human scalp skin <TOGGLE>in vitro</TOGGLE>
42. Localization of specific mRNAs in Xenopus embryos by whole-mount in situ hybridization
43. Evidence for simultaneous derepression of messenger RNA and the guanine nucleotide exchange factor in fertilized sea urchin eggs
44. Direct Inhibition of β-catenin: A new strategy for colorectal cancer.
45. Inhibition of BCL-2 in small cell lung cancer cell lines with oblimersen, an antisense BCL-2 oligodeoxynucleotide (ODN): in vitro and in vivo enhancement of radiation response.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.